Traws Pharma Inc. (NASDAQ: TRAW) received approval from the Human Research Ethics Committee to proceed with Phase 2 studies of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE